EU Moves to Phase Out Animal Testing in Chemical Safety as US Follows Suit

On June 1, the European Commission committed to drive animal testing out of chemical safety checks, adopting a roadmap of more than 330 measures to replace methods that have relied on laboratory animals for decades.

The plan signals a broader transatlantic turn, as regulators in Brussels and Washington race to rebuild safety science around human cells, lab-grown organs, and computer models rather than the mice, rabbits, and dogs of the past.

Recent figures from across the European Union count more than 15 million animals used in regulatory testing, nearly 40 percent of them for chemical safety assessments alone .

In those tests, researchers force animals to swallow or inhale chemicals, or restrain them while dripping substances onto their skin and eyes, then kill them to study the damage. Welfare groups such as Cruelty Free Europe and Humane World for Animals condemn the practice as cruel, and the Commission itself frames the phase-out as an ethical duty to animals as sentient beings.

The plan groups its work under three pillars: developing non-animal test methods, harnessing artificial intelligence and shared data, and deepening cooperation across the 15 regulated fields it covers. The measures include letting companies use the EU's reference laboratory for alternative methods and building a shared chemicals data platform to speed validation.

The Commission built the plan after 91 submissions to a public call for evidence, responding to years of pressure from scientists, industry, and animal-welfare campaigners.

Pressure for the change has mounted as evidence accumulates that animal models predict human biology poorly, a weakness researchers blame for the roughly 86 percent of experimental drugs that fail in human trials.

For medicines, the roadmap proposes cutting repeated-dose toxicology studies for advanced cancers and replacing some live control animals with virtual controls drawn from existing data.

The pharmaceutical industry welcomed the plan, with Kirsty Reid, science-policy director at the drugmakers' federation EFPIA, calling it a step toward predictive, human-relevant methods that protect patients and the environment alike.

Brussels has stressed that the overhaul will keep its safety checks just as protective, even as it retires animal tests, an answer to critics who fear weaker consumer safeguards.

Researchers have spent years building the replacements, among them organoids, tiny lab-grown clusters of human tissue, organ-on-a-chip devices that channel living cells through fluid-filled chips, and computer models that simulate how a compound moves through the body.

Adoption has accelerated, with biomedical studies relying only on non-animal methods quadrupling between 2006 and 2022, though each new method must still clear validation before regulators will trust it.

The United States has pressed in the same direction, with the Food and Drug Administration releasing draft guidance on March 18 that urges developers to favor human-based methods, and Commissioner Marty Makary has faulted animal testing for poorly predicting human results.

The Environmental Protection Agency, under Administrator Lee Zeldin, has recommitted to ending its requests for mammal tests by 2035 and says alternative methods have already spared about 1,600 mice and rats in a single chemical review.

The agency's framework asks developers to prove a method's intended purpose, its relevance to human biology, its technical reliability, and its fitness for a given regulatory decision.

Congress wrote the goal into law in 2016, ordering the EPA to cut vertebrate testing wherever the science allows.

China has poured the equivalent of 382 million dollars into a national organ-emulation program, a sign that the race to replace animals reaches well beyond Europe and the United States.

Stephane Sejourne, the Commission's executive vice-president for industrial strategy, has publicly backed the roadmap as a way to modernize Europe's safety science without lowering its standards.

The science still has limits, and researchers caution that the most tangled biology, from cancer to immune reactions to the reproductive and hormonal systems, defies testing without live animals.

For that reason, the Commission expects the shift to span years, since no validated alternatives yet exist for the hardest tests, making the roadmap a long phase-out rather than an immediate ban.